Provention Bio's TZIELD is the first and only therapy to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. 

According to the complaint, Rite Aid allegedly filled “at least” hundreds of thousands of unlawful prescriptions for controlled substances that lacked legitimate medical purpose, were not for a medically accepted indication or were not issued in the usual course of professional practice.

A new Alzheimer’s disease drug, Leqembi (lecanemab), will be covered by the Veterans Affairs for some patients, making the VA the first insurer to cover the drug.

Wary consumers can be convinced to allow AI into their healthcare habits by communications campaigns tuned to the ancient rhetorical categories of ethos, pathos and logos. 

“Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate technology with the scale and strength of Pfizer’s capabilities and expertise," says Pfizer Chairman and CEO Albert Bourla, PhD.

"Margins are not expected to return to pre-pandemic levels for quite some time," according to a new report.

SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more. 

Researchers across the pond have developed and externally validated an AI model that can predict flareups of ulcerative colitis.